




# Better Bone Health.

Protect Your Independence and Vitality.



# What is Osteoporosis?


Osteoporosis literally means porous bone, is a disease in which the density and quality of bone are reduced. As bones become more porous and fragile, the risk of fracture is greatly increased. The loss of bone occurs silently and progressively. Osteoporosis is often called a silent disease because bone loss occurs without symptoms unless one has fractured.




## Osteoporosis affects both Men and Women

Worldwide,

**1 in 3** women over age 50 will experience osteoporotic fractures, as will



**1 in 5** men aged over 50<sup>1,2,3</sup>



Osteoporosis is estimated to affect 200 million women worldwide – approximately


**1/10**  
of women  
aged 60

**1/5**  
of women  
aged 70

**2/5**  
of women  
aged 80


**2/3**  
of women  
aged 90<sup>4</sup>

# Fractures from Osteoporosis is more common than heart attack, stroke and breast cancer combined<sup>5</sup>



In women over 45 years of age, osteoporosis accounts for more days spent in hospital than many other diseases, including diabetes, myocardial infarction and breast cancer.<sup>6</sup>


## Osteoporosis may have Serious Implications for the Patient



Up to **20%** of patients die in the first year following hip fractures, mostly due to pre-existing medical conditions. **Less than half** those who survive the hip fracture regain their previous level of function<sup>7</sup>



Women who develop a **vertebral fracture** are at substantial risk for additional fracture within the next **1-2 years**<sup>8,9</sup>



Nearly **75%** of hip, spine and distal forearm fractures occur among patients **65 years old or over**<sup>10</sup>

## Poor Patient Compliance is a major problem in the fight against Osteoporosis

There is a range of drug treatment available for postmenopausal osteoporosis. Different studies have consistently shown that, depending on the drug and the patient population, treatment reduces the risk of vertebral fracture by between **30-70%**, nonvertebral fractures by between **15-20%**, and hip fractures up to **40%**.<sup>11,12</sup>

Poor compliance is one of the most important treatment problems. Studies show that only **40%** of patients take treatment for more than one year. At two years, only **20%** of patients are still taking their medication.<sup>13,14</sup>



## What can you do for fight against Osteoporosis

Dual energy X-ray absorptiometry (DXA) scans to measure bone mineral density (BMD) have an important role in the evaluation of individuals at risk of osteoporosis, and in helping clinicians advise patients about the appropriate use of antifracture treatment. BMD results can be interpreted using the World Health Organization T-score definition of osteoporosis, a proven ability to predict fracture risk, proven effectiveness at targeting antifracture therapies, and the ability to monitor response to treatment.<sup>15</sup>

References:

1. Melton LJ, 3rd, Atkinson EJ, O'Connor MK, et al. (1998) Bone density and fracture risk in men. *J Bone Miner Res* 13:1915.
2. Melton LJ, 3rd, Chrischilles EA, Cooper C, et al. (1992) Perspective. How many women have osteoporosis? *J Bone Miner Res* 7:1005.
3. Kanis JA, Johnell O, Oden A, et al. (2000) Long-term risk of osteoporotic fracture in Malmo. *Osteoporos Int* 11:669.
4. Reference: Kanis JA (2007) WHO Technical Report, University of Sheffield, UK: 66.
5. <http://www.ownthebone.org/>
6. Kanis JA, Delmas P, Burckhardt P, et al. (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. *Osteoporos Int* 7:390.
7. Keene GS, Parker MJ, Pryor GA (1993) Mortality and morbidity after hip fractures. *BMJ* 307:1248.
8. Lindsay R, Silverman SL, Cooper C, et al. (2001) Risk of new vertebral fracture in the year following a fracture. *JAMA* 285:320.
9. Dawson-Hughes B, Tosteson AN, Melton LJ, 3rd, et al. (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. *Osteoporos Int* 19:449.
10. Melton LJ, 3rd, Crowson CS, O'Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. *Osteoporos Int* 9:29.
11. Kanis JA, Burlet N, Cooper C, et al. (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 19:399.
12. Black DM, Delmas PD, Eastell R, et al. for the HORIZON Pivotal Fracture Trial (2007) Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. *N Engl J Med* 356:1809.
13. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. *Maturitas* 48:271.
14. Rabenda V, Mertens R, Fabri V, et al. (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. *Osteoporos Int* 19:811.
15. Glen M Blake and Ignac Fogelman, *Postgrad Med J*. 2007 Aug; 83(982): 509-517, The role of DXA bone density scans in the diagnosis and treatment of osteoporosis.

© 2017 General Electric Company – All rights reserved.

GE Healthcare reserves the right to make changes in specifications and features shown herein, or discontinue the product described at any time without notice or obligation. Contact your GE Healthcare representative for the most current information. GE, the GE Monogram and imagination at work are trademarks of General Electric Company. GE Healthcare, a division of General Electric Company. GE Medical Systems, Inc., doing business as GE Healthcare.

